Lynk 7339-002

For patients who have been previously treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD)

Efficacy and Safety of Olaparib in Participants With Previously Treated, Homologous Recombination Repair Mutation or Homologous Recombination Deficiency Positive Advanced Cancer

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Status:

Recruiting

Phase 2 Icon

Trial Phase

The investigational drug is being studied in a group of patients to see if it is safe and effective.

Eligibility

About the Trial

All patients who enroll* in the trial will receive medication while on the study.

  • 100% will receive olaparib

* Patients must be centrally confirmed as HRR mutated, HRD positive, or BRCA mutated and meet all other I/E criteria to enroll in the trial.

Trial Purpose
16

US Trial Locations

Clinical trial sites are places such as hospitals or clinics where the trial is being conducted.

See Locations

National Trial Reference Number

NCT03742895 Read More at clinicaltrials.gov

What Can You Do Next?

If you would like to learn about this clinical trial or see if you can participate, you can:

Contact Our Trial Info Center

To learn more, call 1-888-577-8839

Discuss With Your Doctor

Print this page or Email it to your doctor to discuss at your next visit

Tip: To help with understanding of some clinical terms used on the page, select an underlined term to see what they mean.

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Condition

The disease, disorder, syndrome, illness, or injury that is being studied. Conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
Advanced Solid Neoplasms

Age range

18 — no age maximum

Gender(s)

All

Trial Purpose

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Important information

Participating in a clinical trial is an important decision. Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.

Trial Locations

    Location
    Status
  • Lexington, Kentucky, United States, 40536
    Recruiting
  • Worcester, Massachusetts, United States, 01655
    Recruiting
  • Detroit, Michigan, United States, 48202
    Recruiting
  • Lincoln, Nebraska, United States, 68510
    Recruiting
  • Seattle, Washington, United States, 98101
    Recruiting
  • Fullerton, California, United States, 92835
    Recruiting
  • Tulsa, Oklahoma, United States, 74133
    Recruiting
  • New York, New York, United States, 10065
    Recruiting
  • Sioux Falls, South Dakota, United States, 57104
    Recruiting
  • Atlanta, Georgia, United States, 30322-1013
    Recruiting
  • Augusta, Georgia, United States, 30912
    Recruiting
  • San Francisco, California, United States, 94115
    Recruiting
  • Philadelphia, Pennsylvania, United States, 19124
    Recruiting
  • Baltimore, Maryland, United States, 21201
    Recruiting
  • New York, New York, United States, 10016
    Recruiting
  • Saint George, Utah, United States, 84790
    Recruiting

How to Learn More

When speaking to your doctor, please have the trial reference number available. You can also call 1-888-577-8839 for more information.

Print or email this page.

Trial reference number

A unique identification code given to each clinical trial registered on clinicaltrials.gov.

Lynk number

A unique identification code used by the sponsor to identify a specific trial.
Lynk-7339-002

Official title

A description of the clinical trial that the trial sponsor and clinicians use to identify a specific trial and its purpose.
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Call 1-888-577-8839 to contact our trial information center

Clinical Trials: Important Information to Consider

There is a lot to consider when deciding whether to participate in a clinical study. Any clinical study includes risks, which the study doctor will review with you. Make sure you understand the risks before participating.